| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
QualChoice, our commitment is to your good health. Our vision is to become the health plan in this region that is most preferred by households, businesses, and the medical community.
Agility Therapy is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthPlan Services (HPS) is the nation’s largest independent provider of sales, benefits administration, retention, reform and technology solutions to the insurance and managed care industries. Headquartered in Tampa, Florida, HPS was founded in 1970 and employs 1,500+ associates. HPS stands at the forefront of the insurance industry, providing exchange connectivity, administration, distribution and technology services to insurers of individual, small group, voluntary and association plans, as well as valuable solutions to thousands of brokers and agents, nationwide. Our Go-To-Exchange® platform combines the services of ExchangeLink, SalesLink, ServiceLink and LoyaltyLink products to enable the connectivity, enrollment, reconciliation, eligibility, subsidy and premium billing, member services and renewals for over 5.0 million members, including 2.4 million members on public exchanges and over 1.2 million members on private exchanges. HPS connects 6 of the nation’s largest insurers to public and state exchanges in 39 states and has a market share of 21%.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.